# A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)

> **NCT07746089** · PHASE3 · NOT_YET_RECRUITING · sponsor: **argenx** · enrollment: 105 (estimated)

## Conditions studied

- Congenital Myasthenic Syndrome
- CMS

## Interventions

- **BIOLOGICAL:** Adimanebart IV
- **OTHER:** Placebo IV

## Key facts

- **NCT ID:** NCT07746089
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2030-10
- **Final completion:** 2030-10
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746089, "A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*